As a member of the Leukemia Research Program at the OSUCCC – James, my clinical and translational research focus is on novel therapeutics in myeloid diseases, with a special focus in disease progression from cytopenia and early-stage MDS to AML. I am the principal investigator for numerous investigator-initiated clinical trials based on laboratory science, including a promising study that looks at the novel combination of targeted therapies for myeloid malignancies. I am also the national lead and site investigator for several early-phase, industry-supported MDS and AML studies in both upfront and relapsed/refractory disease. My work has appeared in such peer-reviewed publications as Nature Medicine, Oncotarget, Blood Advances and Leukemia.